Date published: 2025-10-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

Montelukast Dicyclohexylamine Salt (CAS 577953-88-9)

0.0(0)
Write a reviewAsk a question

Application:
Montelukast Dicyclohexylamine Salt is a CysLT1 Receptor (leukotriene D4-receptor) antagonist
CAS Number:
577953-88-9
Purity:
≥98%
Molecular Weight:
767.50
Molecular Formula:
C47H59ClN2O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Montelukast Dicyclohexylamine Salt is an analogue of Montelukast (sc-202231), a selective CysLT1 receptor antagonist, which blocks leukotriene D4 (LTD4) and secondary ligands such as LTC4 and LTE4 from binding to the receptor. Studies indicate that LTD4 functions biologically by increasing bronchoconstriction, microvascular permeability, and are vasoconstriction of coronary arteries. It is known that inhibition of leukotriene D4 is competitive. Leukotriene D4 is such as important biochemical mediator in various biochemical pathways, so Montelukast Dicyclohexylamine Salt is a useful tool in regulating these pathways. Furthermore, studies on rat colitis indicate that Montelukast Dicyclohexylamine Salt can reduce the expression of COX-2 and amplify the production of PGE2 (Prostaglandin E2 - sc-201225).


Montelukast Dicyclohexylamine Salt (CAS 577953-88-9) References

  1. Characterization of the human cysteinyl leukotriene CysLT1 receptor.  |  Lynch, KR., et al. 1999. Nature. 399: 789-93. PMID: 10391245
  2. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.  |  Sarau, HM., et al. 1999. Mol Pharmacol. 56: 657-63. PMID: 10462554
  3. Characterization of the human cysteinyl leukotriene 2 receptor.  |  Heise, CE., et al. 2000. J Biol Chem. 275: 30531-6. PMID: 10851239
  4. Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.  |  Holma, R., et al. 2001. Eur J Pharmacol. 429: 309-18. PMID: 11698051
  5. The role of leukotrienes in allergic rhinitis.  |  Peters-Golden, M. and Henderson, WR. 2005. Ann Allergy Asthma Immunol. 94: 609-18; quiz 618-20, 669. PMID: 15984591
  6. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.  |  Luethi, D., et al. 2019. Biochem Pharmacol. 164: 129-138. PMID: 30981875
  7. In vitro and in vivo metabolism of psilocybin's active metabolite psilocin.  |  Thomann, J., et al. 2024. Front Pharmacol. 15: 1391689. PMID: 38741590
  8. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.  |  Reiss, TF., et al. 1998. Arch Intern Med. 158: 1213-20. PMID: 9625400
  9. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.  |  Leff, JA., et al. 1998. N Engl J Med. 339: 147-52. PMID: 9664090

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Montelukast Dicyclohexylamine Salt, 1 mg

sc-211923
1 mg
$320.00